CompletedNot Applicable

Program Cell Death Receptor 1 in Mycobacterium Avium Complex Lung Disease

Taiwan112 participantsStarted 2015-01

Plain-language summary

1. To understand the components of PBMC in MAC-LD patients, including T cells, B cells, nature killer cells, and monocyte. 2. To confirm the phenomenon of reduced PBMC response in MAC-LD patients 3. To study the proportion of apoptosis and PD-1 expression in T cells among MAC-LD patients, MAC colonizers, patients with tuberculosis, and healthy controls. 4. To study the apoptosis and PD-1/PD-L1 expression in T cells/macrophage from bronchial lavage among MAC-LD patients, MAC colonizers, patients with tuberculosis, 5. To examine the PD-1 gene polymorphism and the correlation with MAC-LD.

Who can participate

Age range20 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age ≥ 20 years * MAC lung disease: Diagnosis is based on the guidelines by American Thoracic Society. In brief, there should be pulmonary symptoms, comparable findings in chest image and appropriate exclusion other possible causes as well as meeting the microbiology criteria. * MAC pulmonary colonizers: Those without fulfilling the diagnostic criteria but having at least one set of positive sputum for MAC are defined. * Healthy controls: * Active tuberculosis group: patients with pulmonary tuberculosis diagnosed by positive respiratory culture Exclusion Criteria: * Patients who have acquired immunodeficiency syndrome

What they're measuring

Percent of disease progression

Timeframe: 2 year

Trial details

NCT IDNCT02779049

SponsorNational Taiwan University Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2016-07

View on ClinicalTrials.gov More Mycobacterium Avium trials